Unknown

Dataset Information

0

Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors.

ABSTRACT: To explore the potential use of CDK inhibitors in pancreatic ductal adenocarcinoma (PDAC) therapy, a series of novel 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives was designed, synthesised, and investigated for inhibition on both CDK kinase activity and cellular proliferation of pancreatic cancer. Most of new sulphonamide-containing derivatives demonstrated strong inhibitory activity on CDK9 and obvious anti-proliferative activity in cell culture. Moreover, two new compounds suppressed cell proliferation of multiple human pancreatic cancer cell lines. The most potent compound 2g inhibited cancer cell proliferation by blocking Rb phosphorylation and induced apoptosis via downregulation of CDK9 downstream proteins Mcl-1 and c-Myc in MIA PaCa-2 cells. CDK9 knockdown experiment suggests its anti-proliferative activity is mainly mediated by CDK9. Additionally, 2g displayed moderate tumour inhibition effect in AsPC-1 derived xenograft mice model. Altogether, this study provided a new start for further optimisation to develop potential CDK inhibitor candidates for PDAC treatment by alone or combination use.

SUBMITTER: Yang B 

PROVIDER: S-EPMC9858427 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors.

Yang Bo B   Quan Yanni Y   Zhao Wuli W   Ji Yingjie Y   Yang Xiaotang X   Li Jianrui J   Li Yi Y   Liu Xiujun X   Wang Ying Y   Li Yanping Y  

Journal of enzyme inhibition and medicinal chemistry 20231201 1

To explore the potential use of CDK inhibitors in pancreatic ductal adenocarcinoma (PDAC) therapy, a series of novel 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives was designed, synthesised, and investigated for inhibition on both CDK kinase activity and cellular proliferation of pancreatic cancer. Most of new sulphonamide-containing derivatives demonstrated strong inhibitory activity on CDK9 and obvious anti-proliferative activity in cell culture. Moreover, two new compounds  ...[more]

Similar Datasets

Unknown Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation.
| S-EPMC10536156 | biostudies-literature
Unknown Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine derivatives as novel EGFR<sup>L858R/T790M</sup> inhibitors.
| S-EPMC10150624 | biostudies-literature
Unknown Design, synthesis, antitumor evaluation, and molecular docking of novel pyrrolo[2,3-d]pyrimidine as multi-kinase inhibitors.
| S-EPMC10205775 | biostudies-literature
Unknown Novel 5'-Norcarbocyclic Derivatives of Bicyclic Pyrrolo- and Furano[2,3-d]Pyrimidine Nucleosides.
| S-EPMC6222425 | biostudies-literature
Unknown Design, synthesis, in vitro anticancer, molecular docking and SAR studies of new series of pyrrolo[2,3-d]pyrimidine derivatives.
| S-EPMC10463376 | biostudies-literature
Unknown Discovery of New Pyrrolo[2,3-<i>d</i>]pyrimidine Derivatives as Potential Multi-Targeted Kinase Inhibitors and Apoptosis Inducers.
| S-EPMC10536928 | biostudies-literature
Unknown 4-Chloro-1H-pyrrolo-[2,3-d]pyrimidine.
| S-EPMC3435690 | biostudies-literature
Unknown Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical and nonclassical pyrrolo[2,3-d]pyrimidine antifolates(1).
| S-EPMC2547132 | biostudies-literature
Unknown Synthesis and biological evaluation of pyrido[2,3-d]pyrimidine-2,4-dione derivatives as eEF-2K inhibitors.
| S-EPMC6473179 | biostudies-literature
Unknown Design, synthesis and biological evaluation of 1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine derivatives as potent fibroblast growth factor receptor inhibitors.
| S-EPMC9033946 | biostudies-literature